Jiangsu Hengrui Pharmaceuticals Co., Ltd. sold BRVE
August 7, 2026 · Form 4 insider transaction
Jiangsu Hengrui Pharmaceuticals Co., Ltd. sold 32,500,000 shares of Braveheart Bio, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 3 days after the transaction.
Direction
Disposed (sell-side)
Shares
32,500,000
Price
$0.00
Total value
N/A
Role—
CompanyBraveheart Bio, Inc. (BRVE)
SecurityNon-voting Series A preferred stock
Transaction codeC: Conversion of a derivative
Transaction dateAugust 7, 2026
Filing dateAugust 10, 2026
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The non-voting Series A preferred stock (the "Preferred Stock") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.